Outsourcing Biotech to China Isn't Worth the Risk

Jacky Wong’s “The Next U.S.-China Battleground: Biotech” (Heard on the Street, Sept. 17) highlights China’s outsize role in the manufacturing of active pharmaceutical ingredients, the key components of the lifesaving medications we use daily in the U.S.

Offshoring biomanufacturing threatens our nation’s ability to access vital materials. While I applaud President Biden’s recent executive order to accelerate biotechnology innovation, our overreliance on outsourcing life-sciences research to China has put patients, providers and the healthcare supply chain at risk.

Michael J. Alkire, President and CEO, Premier Inc.

Full Letter to the Editor (requires WSJ membership)